BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 22287477)

  • 1. Acute coronary syndrome upon receiving carmustine infusion before autologous stem-cell transplantation.
    Waibel Pachinger C; Rosselet A; Berthouzoz S; Luthi F; Ketterer N
    Hematol Oncol; 2012 Dec; 30(4):216-8. PubMed ID: 22287477
    [No Abstract]   [Full Text] [Related]  

  • 2. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
    Cote GM; Hochberg EP; Muzikansky A; Hochberg FH; Drappatz J; McAfee SL; Batchelor TT; LaCasce AS; Fisher DC; Abramson JS; Armand P; Chen YB
    Biol Blood Marrow Transplant; 2012 Jan; 18(1):76-83. PubMed ID: 21749848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Headache, circumoral paresthesia, and facial flushing associated with high-dose carmustine infusion.
    Woo MH; Ippoliti C; Bruton J; Mehra R; Champlin R; Przepiorka D
    Bone Marrow Transplant; 1997 Apr; 19(8):845-7. PubMed ID: 9134180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
    Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
    J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
    Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E
    Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Autologous transplant with BEAM protocol in lymphoma].
    Caballero D; Rubio V; Rifon J; Heras I; García-Sanz R; Vidriales B; Pérez-Simón JA; del Cañizo C; González M; León A; Jean-Paul E; Rocha E; Vicente V; San Miguel JF
    Sangre (Barc); 1997 Apr; 42 Suppl 1():46-9. PubMed ID: 9381303
    [No Abstract]   [Full Text] [Related]  

  • 7. Autologous blood stem cell transplantation for Hodgkin and non-Hodgkin lymphoma: complications and outcome.
    Kumar L; Ganessan P; Ghosh I; Panda D; Gogia A; Mandhania S
    Natl Med J India; 2010; 23(6):330-5. PubMed ID: 21561042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Successful treatment with foscarnet for disseminated varicella-zoster infection after reduced intensity stem cell transplantation in a case of relapsed refractory central nervous system lymphoma].
    Aoyama Y; Yamamura R; Shima E; Nakamae H; Makita K; Hasegawa T; Sakamoto C; Terada Y; Kho G; Ohta K; Yamane T; Takubo T; Hino M
    Rinsho Ketsueki; 2003 Jul; 44(7):451-5. PubMed ID: 12931563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Tale of Two Eras: The Story of Autologous Stem Cell Transplantation with and without Thiotepa for Primary Central Nervous System Lymphoma.
    Hu B
    Biol Blood Marrow Transplant; 2019 May; 25(5):e141-e142. PubMed ID: 30878604
    [No Abstract]   [Full Text] [Related]  

  • 10. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.
    Phillips GL; Meisenberg BR; Reece DE; Adams VR; Badros AZ; Brunner JL; Fenton RG; Filicko J; Grosso DL; Hale GA; Howard DS; Johnson VP; Kniska A; Marshall KW; Mookerjee B; Nath R; Rapoport AP; Sarkodee-Adoo C; Takebe N; Vesole DH; Wagner JL; Flomenberg N
    Bone Marrow Transplant; 2004 Apr; 33(8):781-7. PubMed ID: 14767498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
    Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
    Kim JE; Lee DH; Yoo C; Kim S; Kim SW; Lee JS; Park CJ; Huh J; Suh C
    Leuk Res; 2011 Feb; 35(2):183-7. PubMed ID: 20684990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy.
    Molina A; Krishnan AY; Nademanee A; Zabner R; Sniecinski I; Zaia J; Forman SJ
    Cancer; 2000 Aug; 89(3):680-9. PubMed ID: 10931469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful therapy with high-dose steroids and cyclosporine for the treatment of carmustine-mediated lung injury.
    Zappasodi P; Vitulo P; Volpini E; Castagnola C; Nascimbene C; Corso A
    Ann Hematol; 2002 Jun; 81(6):347-9. PubMed ID: 12107568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
    Wadhwa PD; Fu P; Koc ON; Cooper BW; Fox RM; Creger RJ; Bajor DL; Bedi T; Laughlin MJ; Payne J; Gerson SL; Lazarus HM
    Biol Blood Marrow Transplant; 2005 Jan; 11(1):13-22. PubMed ID: 15625540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of hematopoietic stem cell transplantation in the treatment of non-Hodgkin's lymphoma.
    Bierman PJ; Phillips GL
    Cancer Treat Res; 2009; 144():357-97. PubMed ID: 19779882
    [No Abstract]   [Full Text] [Related]  

  • 17. First-line autologous stem cell transplantation in primary CNS lymphoma.
    Brevet M; Garidi R; Gruson B; Royer B; Vaida I; Damaj G
    Eur J Haematol; 2005 Oct; 75(4):288-92. PubMed ID: 16146534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma.
    Wildes TM; Augustin KM; Sempek D; Zhang QJ; Vij R; Dipersio JF; Devine SM
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):840-6. PubMed ID: 18541205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide.
    Dean RM; Pohlman B; Sweetenham JW; Sobecks RM; Kalaycio ME; Smith SD; Copelan EA; Andresen S; Rybicki LA; Curtis J; Bolwell BJ
    Br J Haematol; 2010 Jan; 148(2):226-34. PubMed ID: 19821828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
    Liu HW; Seftel MD; Rubinger M; Szwajcer D; Demers A; Nugent Z; Schroeder G; Butler JB; Cooke A
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):513-20. PubMed ID: 20137862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.